Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cabaletta Bio

1.99
+0.190010.56%
Post-market: 1.98-0.0107-0.54%19:50 EDT
Volume:4.57M
Turnover:8.63M
Market Cap:178.99M
PE:-0.78
High:2.00
Open:1.75
Low:1.70
Close:1.80
Loading ...

Cabaletta Bio Is Maintained at Buy by Guggenheim

Dow Jones
·
16 May

Cabaletta Bio price target raised to $25 from $23 at Guggenheim

TIPRANKS
·
16 May

BRIEF-Cabaletta Bio Announces 2027 Rese-Cel BLA Submission Anticipated In Myositis Following Recent FDA Alignment On Registrational Cohorts

Reuters
·
15 May

Cabaletta Bio Inc. Unveils Corporate Presentation on Pioneering Cellular Therapies for Autoimmune Diseases

Reuters
·
15 May

Cabaletta Bio Announces 2027 Rese-Cel Bla Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

THOMSON REUTERS
·
15 May

Cabaletta Bio Inc: Systemic Sclerosis Registrational Discussions With FDA Anticipated in 4Q25

THOMSON REUTERS
·
15 May

Cabaletta Bio Inc: Sle and Ln Registrational Discussions With FDA Anticipated in 3Q25

THOMSON REUTERS
·
15 May

Cabaletta Bio Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters
·
09 May

Cabaletta Bio’s Clinical Progress and Strategic Direction Bolster Buy Rating

TIPRANKS
·
02 Apr

UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating

MT Newswires Live
·
01 Apr

Cabaletta Bio Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
01 Apr

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Apr

Cabaletta Bio price target lowered to $7 from $10 at UBS

TIPRANKS
·
01 Apr

Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating

TIPRANKS
·
01 Apr

Cabaletta Bio Inc : Morgan Stanley Cuts Target Price to $22 From $30

THOMSON REUTERS
·
01 Apr

Cabaletta Bio, Inc. : Wells Fargo Cuts Target Price to $3 From $6

THOMSON REUTERS
·
01 Apr

Cabaletta Bio price target lowered to $13 from $26 at Stifel

TIPRANKS
·
01 Apr

Cabaletta Bio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
31 Mar

Cabaletta Bio Q4 2024 GAAP EPS $(0.65) Misses $(0.63) Estimate, Operational Runway Into 1H26 With Cash And Cash Equivalents Of $164M As Of December 31, 2024

Benzinga
·
31 Mar

Cabaletta Bio Q4 Net Income USD -32.586 Million

THOMSON REUTERS
·
31 Mar